Epidemiology and hereditary aspects of acute leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent projections for the USA estimate that 6590 patients are diagnosed annually with acute lymphocytic leukemia (ALL) and 19,950 with acute myeloid leukemia (AML), while approximately 1430 patients die from ALL and 10,430 from AML (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Together these forms of acute leukemia represent about 1.6% of all newly diagnosed cancers and 2.0% of all cancer deaths in the USA (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Advances in the understanding of immunology and molecular/genetic features of the acute leukemias along with laboratory improvements in immunophenotyping and cytogenetic characterization have led to the recognition of molecularly defined subtypes of ALL and AML, targeted therapeutics, and recognition of distinct prognostic groups. The most recent World Health Organization (WHO) classification of hematopoietic malignancies considers three major categories of acute leukemia: AML and related myeloid precursor neoplasms, precursor lymphoid neoplasms (encompassing the entities previously known as ALL), and acute leukemias of ambiguous lineage (World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer, 2008). Consistent with classifications used in cancer registries, to date most epidemiologic investigations have considered all acute leukemias combined or the broad categories of ALL and AML, although an increasing number of studies, especially those of genetic risk factors, examine cases by molecular subtype. Traditionally pediatric acute leukemias, defined either as those diagnosed at 0-14 or 0-19 years of age, have been studied separately from that in adults.

Original languageEnglish (US)
Title of host publicationNeoplastic Diseases of the Blood
PublisherSpringer International Publishing
Pages179-195
Number of pages17
ISBN (Electronic)9783319642635
ISBN (Print)9783319642628
DOIs
StatePublished - Jan 1 2018

Fingerprint

Leukemia
Epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Neoplasms
International Agencies
Immunophenotyping
Lymphoid Tissue
Hematologic Neoplasms
Allergy and Immunology
Cytogenetics
Registries
Molecular Biology
Pediatrics
Research

Keywords

  • Chemical etiology
  • Familial acute leukemia
  • Leukemia genetics
  • Radiation etiology
  • Seasonal influence on acute leukemia

Cite this

Spector, L. G., Marcotte, E. L., Kehm, R., & Poynter, J. (2018). Epidemiology and hereditary aspects of acute leukemia. In Neoplastic Diseases of the Blood (pp. 179-195). Springer International Publishing. https://doi.org/10.1007/978-3-319-64263-5_13

Epidemiology and hereditary aspects of acute leukemia. / Spector, Logan G; Marcotte, Erin L; Kehm, Rebecca; Poynter, Jenny.

Neoplastic Diseases of the Blood. Springer International Publishing, 2018. p. 179-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Spector, LG, Marcotte, EL, Kehm, R & Poynter, J 2018, Epidemiology and hereditary aspects of acute leukemia. in Neoplastic Diseases of the Blood. Springer International Publishing, pp. 179-195. https://doi.org/10.1007/978-3-319-64263-5_13
Spector LG, Marcotte EL, Kehm R, Poynter J. Epidemiology and hereditary aspects of acute leukemia. In Neoplastic Diseases of the Blood. Springer International Publishing. 2018. p. 179-195 https://doi.org/10.1007/978-3-319-64263-5_13
Spector, Logan G ; Marcotte, Erin L ; Kehm, Rebecca ; Poynter, Jenny. / Epidemiology and hereditary aspects of acute leukemia. Neoplastic Diseases of the Blood. Springer International Publishing, 2018. pp. 179-195
@inbook{9fa8962ff90043db951ea28578b3fd24,
title = "Epidemiology and hereditary aspects of acute leukemia",
abstract = "Recent projections for the USA estimate that 6590 patients are diagnosed annually with acute lymphocytic leukemia (ALL) and 19,950 with acute myeloid leukemia (AML), while approximately 1430 patients die from ALL and 10,430 from AML (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Together these forms of acute leukemia represent about 1.6{\%} of all newly diagnosed cancers and 2.0{\%} of all cancer deaths in the USA (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Advances in the understanding of immunology and molecular/genetic features of the acute leukemias along with laboratory improvements in immunophenotyping and cytogenetic characterization have led to the recognition of molecularly defined subtypes of ALL and AML, targeted therapeutics, and recognition of distinct prognostic groups. The most recent World Health Organization (WHO) classification of hematopoietic malignancies considers three major categories of acute leukemia: AML and related myeloid precursor neoplasms, precursor lymphoid neoplasms (encompassing the entities previously known as ALL), and acute leukemias of ambiguous lineage (World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer, 2008). Consistent with classifications used in cancer registries, to date most epidemiologic investigations have considered all acute leukemias combined or the broad categories of ALL and AML, although an increasing number of studies, especially those of genetic risk factors, examine cases by molecular subtype. Traditionally pediatric acute leukemias, defined either as those diagnosed at 0-14 or 0-19 years of age, have been studied separately from that in adults.",
keywords = "Chemical etiology, Familial acute leukemia, Leukemia genetics, Radiation etiology, Seasonal influence on acute leukemia",
author = "Spector, {Logan G} and Marcotte, {Erin L} and Rebecca Kehm and Jenny Poynter",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-64263-5_13",
language = "English (US)",
isbn = "9783319642628",
pages = "179--195",
booktitle = "Neoplastic Diseases of the Blood",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Epidemiology and hereditary aspects of acute leukemia

AU - Spector, Logan G

AU - Marcotte, Erin L

AU - Kehm, Rebecca

AU - Poynter, Jenny

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Recent projections for the USA estimate that 6590 patients are diagnosed annually with acute lymphocytic leukemia (ALL) and 19,950 with acute myeloid leukemia (AML), while approximately 1430 patients die from ALL and 10,430 from AML (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Together these forms of acute leukemia represent about 1.6% of all newly diagnosed cancers and 2.0% of all cancer deaths in the USA (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Advances in the understanding of immunology and molecular/genetic features of the acute leukemias along with laboratory improvements in immunophenotyping and cytogenetic characterization have led to the recognition of molecularly defined subtypes of ALL and AML, targeted therapeutics, and recognition of distinct prognostic groups. The most recent World Health Organization (WHO) classification of hematopoietic malignancies considers three major categories of acute leukemia: AML and related myeloid precursor neoplasms, precursor lymphoid neoplasms (encompassing the entities previously known as ALL), and acute leukemias of ambiguous lineage (World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer, 2008). Consistent with classifications used in cancer registries, to date most epidemiologic investigations have considered all acute leukemias combined or the broad categories of ALL and AML, although an increasing number of studies, especially those of genetic risk factors, examine cases by molecular subtype. Traditionally pediatric acute leukemias, defined either as those diagnosed at 0-14 or 0-19 years of age, have been studied separately from that in adults.

AB - Recent projections for the USA estimate that 6590 patients are diagnosed annually with acute lymphocytic leukemia (ALL) and 19,950 with acute myeloid leukemia (AML), while approximately 1430 patients die from ALL and 10,430 from AML (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Together these forms of acute leukemia represent about 1.6% of all newly diagnosed cancers and 2.0% of all cancer deaths in the USA (Siegel et al., CA Cancer J Clin 66(1):7-30, 2016). Advances in the understanding of immunology and molecular/genetic features of the acute leukemias along with laboratory improvements in immunophenotyping and cytogenetic characterization have led to the recognition of molecularly defined subtypes of ALL and AML, targeted therapeutics, and recognition of distinct prognostic groups. The most recent World Health Organization (WHO) classification of hematopoietic malignancies considers three major categories of acute leukemia: AML and related myeloid precursor neoplasms, precursor lymphoid neoplasms (encompassing the entities previously known as ALL), and acute leukemias of ambiguous lineage (World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer, 2008). Consistent with classifications used in cancer registries, to date most epidemiologic investigations have considered all acute leukemias combined or the broad categories of ALL and AML, although an increasing number of studies, especially those of genetic risk factors, examine cases by molecular subtype. Traditionally pediatric acute leukemias, defined either as those diagnosed at 0-14 or 0-19 years of age, have been studied separately from that in adults.

KW - Chemical etiology

KW - Familial acute leukemia

KW - Leukemia genetics

KW - Radiation etiology

KW - Seasonal influence on acute leukemia

UR - http://www.scopus.com/inward/record.url?scp=85047034221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047034221&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-64263-5_13

DO - 10.1007/978-3-319-64263-5_13

M3 - Chapter

SN - 9783319642628

SP - 179

EP - 195

BT - Neoplastic Diseases of the Blood

PB - Springer International Publishing

ER -